Thermo Fisher Adds CTS DynaXS to Bioreactor Range

Thermo Fisher Scientific has launched the Gibco CTS DynaXS Single Use Bioreactor, a stirred-tank platform designed to bridge process development and cGMP clinical manufacturing for cell therapies. Announced on 4 May 2026 from Waltham, Massachusetts, the system extends Thermo Fisher’s existing Cell Therapy Systems range into the scale-up segment of the workflow. The launch comes as cell therapy developers face mounting pressure to industrialise production beyond static culture.

The CTS DynaXS sits within Thermo Fisher’s wider Cell Therapy Systems portfolio, which covers cell isolation, activation, expansion and downstream processing. The new bioreactor adds a stirred-tank, single-use option engineered around a broad operating range across volumes, cell types and applications, removing a practical bottleneck for developers moving from bench-scale process work to clinical-grade production on the same underlying platform. The design prioritises process control consistency through scale-up rather than forcing platform changes between development and manufacturing.

Sara Henneman, vice president and general manager of Thermo Fisher’s cell culture and cell therapy business, framed the launch around the company’s commitment to integrated end-to-end solutions that simplify scale and strengthen process control for therapies intended for patient use. Andy Campbell, senior director of R&D, pointed to customer demand for platforms that grow with the pipeline. The launch also responds to a structural shift in the category, with cell therapy moving beyond oncology into autoimmune disease and other indications, each carrying different process and scale requirements.

What’s interesting commercially is the indication mix. Oncology has driven cell therapy investment for a decade, but autoimmune programmes are now pulling forward at scale, with different patient populations and production economics. Platforms like the CTS DynaXS are how suppliers prepare for that broadening, and Thermo Fisher’s bet here is that the next wave of cell therapy commercialisation runs through standardised, integrated bioprocessing infrastructure.